About C-type lectin domain family 18 member C
C-type lectin domain family 18 member C (CLEC18C) is a protein
from Homo sapiens identified by UniProt accession
Q8NCF0, 446 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | C-type lectin domain family 18 member C |
| UniProt accession | Q8NCF0 |
| Gene | CLEC18C |
| Organism | Homo sapiens |
| Length | 446 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (11)
Diseases linked to this target (Open Targets).
- haptoglobin measurement · score 0.23
- lymphocyte count · score 0.14
- amino acid measurement · score 0.07
- blood metabolite measurement · score 0.06
- protein measurement · score 0.06
- urate measurement · score 0.05
- smoking status measurement · score 0.03
- smoking behavior · score 0.02
- body height · score 0.02
- gonorrhea · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NCF0-F1 | alphafold | PREDICTED | 82.11 | — |
Amino-acid sequence (446 residues)
MLHPETSPGR GHLLAVLLAL LGTAWAEVWP PQLQEQAPMA GALNRKESFL LLSLHNRLRS WVQPPAADMR RLDWSDSLAQ LAQARAALCG IPTPSLASGL WRTLQVGWNM QLLPAGLASF VEVVSLWFAE GQRYSHAAGE CARNATCTHY TQLVWATSSQ LGCGRHLCSA GQAAIEAFVC AYSPRGNWEV NGKTIVPYKK GAWCSLCTAS VSGCFKAWDH AGGLCEVPRN PCRMSCQNHG RLNISTCHCH CPPGYTGRYC QVRCSLQCVH GRFREEECSC VCDIGYGGAQ CATKVHFPFH TCDLRIDGDC FMVSSEADTY YRARMKCQRK GGVLAQIKSQ KVQDILAFYL GRLETTNEVI DSDFETRNFW IGLTYKTAKD SFRWATGEHQ AFTSFAFGQP DNHGFGNCVE LQASAAFNWN NQRCKTRNRY ICQFAQEHIS RWGPGS
Explore C-type lectin domain family 18 member C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets